List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/403596/publications.pdf Version: 2024-02-01



EVAN I RDITTAIN

#	Article	IF	CITATIONS
1	A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension. European Respiratory Journal, 2018, 51, 1702638.	6.7	183
2	Fatty Acid Metabolic Defects and Right Ventricular Lipotoxicity in Human Pulmonary Arterial Hypertension. Circulation, 2016, 133, 1936-1944.	1.6	169
3	A Metabolic Basis for Endothelial-to-Mesenchymal Transition. Molecular Cell, 2018, 69, 689-698.e7.	9.7	164
4	Clinical and Biological Insights Into Combined Post- and Pre-Capillary Pulmonary Hypertension. Journal of the American College of Cardiology, 2016, 68, 2525-2536.	2.8	160
5	Evidence for Right Ventricular Lipotoxicity in Heritable Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 325-334.	5.6	146
6	Prognostic Effect and Longitudinal Hemodynamic Assessment of Borderline Pulmonary Hypertension. JAMA Cardiology, 2017, 2, 1361.	6.1	122
7	Thermodilution vs Estimated Fick Cardiac Output Measurement in Clinical Practice. JAMA Cardiology, 2017, 2, 1090.	6.1	91
8	Mechanisms of Lipid Accumulation in the Bone Morphogenetic Protein Receptor Type 2 Mutant Right Ventricle. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 719-728.	5.6	75
9	Association of Mild Echocardiographic Pulmonary Hypertension With Mortality and Right Ventricular Function. JAMA Cardiology, 2019, 4, 1112.	6.1	73
10	Human PAH is characterized by a pattern of lipid-related insulin resistance. JCI Insight, 2019, 4, .	5.0	69
11	Mobile Health Technologies in Cardiopulmonary Disease. Chest, 2020, 157, 654-664.	0.8	59
12	Dysfunctional BMPR2 signaling drives an abnormal endothelial requirement for glutamine in pulmonary arterial hypertension. Pulmonary Circulation, 2017, 7, 186-199.	1.7	57
13	Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects. European Respiratory Journal, 2017, 50, 1602337.	6.7	55
14	Lack of a Tricuspid Regurgitation Doppler Signal and Pulmonary Hypertension by Invasive Measurement. Journal of the American Heart Association, 2018, 7, .	3.7	53
15	Challenges Facing Early Career Academic Cardiologists. Journal of the American College of Cardiology, 2014, 63, 2199-2208.	2.8	51
16	Impact of Diabetes on Survival and Right Ventricular Compensation in Pulmonary Arterial Hypertension. Pulmonary Circulation, 2014, 4, 311-318.	1.7	50
17	Mechanistic Phase II Clinical Trial of Metformin in Pulmonary Arterial Hypertension. Journal of the American Heart Association, 2020, 9, e018349.	3.7	44
18	Six-minute walk distance in healthy young adults. Respiratory Medicine, 2020, 165, 105933.	2.9	43

#	Article	IF	CITATIONS
19	Redefining pulmonary hypertension. Lancet Respiratory Medicine,the, 2018, 6, 168-170.	10.7	41
20	Hemodynamic Evidence of Vascular Remodeling in Combined Post―and Precapillary Pulmonary Hypertension. Pulmonary Circulation, 2016, 6, 313-321.	1.7	38
21	Elevation of Plasma Cell-Free Hemoglobin in Pulmonary Arterial Hypertension. Chest, 2014, 146, 1478-1485.	0.8	34
22	Unexpectedly Low Natriuretic Peptide Levels in Patients With HeartÂFailure. JACC: Heart Failure, 2021, 9, 192-200.	4.1	32
23	Prostanoids But Not Oral Therapies ImproveÂRight Ventricular Function in Pulmonary Arterial Hypertension. JACC: Heart Failure, 2013, 1, 300-307.	4.1	31
24	Increased Echocardiographic Pulmonary Pressure in HIV-infected and -uninfected Individuals in the Veterans Aging Cohort Study. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 923-932.	5.6	31
25	Shorter Survival in Familial versus Idiopathic Pulmonary Arterial Hypertension is Associated with Hemodynamic Markers of Impaired Right Ventricular Function. Pulmonary Circulation, 2013, 3, 589-598.	1.7	30
26	Features Associated With Discordance Between Pulmonary Arterial Wedge Pressure and Left Ventricular End Diastolic Pressure in Clinical Practice. Chest, 2018, 154, 1099-1107.	0.8	29
27	Right Ventricular Plasticity and Functional Imaging. Pulmonary Circulation, 2012, 2, 309-326.	1.7	27
28	The transpulmonary ratio of endothelin 1 is elevated in patients with preserved left ventricular ejection fraction and combined pre―and postâ€capillary pulmonary hypertension. Pulmonary Circulation, 2018, 8, 1-8.	1.7	27
29	Mendelian randomisation analysis of red cell distribution width in pulmonary arterial hypertension. European Respiratory Journal, 2020, 55, 1901486.	6.7	26
30	FIB-4 stage of liver fibrosis is associated with incident heart failure with preserved, but not reduced, ejection fraction among people with and without HIV or hepatitis C. Progress in Cardiovascular Diseases, 2020, 63, 184-191.	3.1	25
31	Acute Improvement in Right Ventricular Function after Treatment of Presumed Massive Pulmonary Embolism with Thrombolytics. Pulmonary Circulation, 2012, 2, 522-524.	1.7	20
32	Effect of Acute Arteriolar Vasodilation on Capacitance and Resistance in Pulmonary Arterial Hypertension. Chest, 2015, 147, 1080-1085.	0.8	20
33	Echocardiographic Pulmonary Artery Systolic Pressure in the Coronary Artery Risk Development in Young Adults (CARDIA) Study: Associations With Race and Metabolic Dysregulation. Journal of the American Heart Association, 2017, 6, .	3.7	20
34	Diabetes Mellitus Associates with Increased Right Ventricular Afterload and Remodeling in Pulmonary Arterial Hypertension. American Journal of Medicine, 2018, 131, 702.e7-702.e13.	1.5	20
35	Natriuretic peptide receptor C contributes to disproportionate right ventricular hypertrophy in a rodent model of obesity-induced heart failure with preserved ejection fraction with pulmonary hypertension. Pulmonary Circulation, 2019, 9, 204589401987859.	1.7	20
36	Adverse physiologic effects of Western diet on right ventricular structure and function: role of lipid accumulation and metabolic therapy. Pulmonary Circulation, 2019, 9, 1-9.	1.7	20

#	Article	IF	CITATIONS
37	Cirrhotic cardiomyopathy: Appraisal of the original and revised criteria in predicting posttransplant cardiac outcomes. Liver Transplantation, 2022, 28, 1321-1331.	2.4	20
38	Right Ventricular Protein Expression Profile in End‣tage Heart Failure. Pulmonary Circulation, 2015, 5, 481-497.	1.7	19
39	A Fluid Challenge Test for the Diagnosis of Occult Heart Failure. Chest, 2021, 159, 791-797.	0.8	19
40	Echocardiographic Assessment of the Right Heart in Mice. Journal of Visualized Experiments, 2013, , .	0.3	18
41	Bone Marrow–Derived Proangiogenic Cells Mediate Pulmonary Arteriole Stiffening via Serotonin 2B Receptor Dependent Mechanism. Circulation Research, 2018, 123, e51-e64.	4.5	17
42	Racial differences in patients referred for right heart catheterization and risk of pulmonary hypertension. Pulmonary Circulation, 2018, 8, 1-9.	1.7	17
43	Feasibility and Diagnostic Potential of Pulmonary Transit Time Measurement by Contrast Echocardiography: A Pilot Study. Echocardiography, 2015, 32, 1564-1571.	0.9	16
44	Unbiased Phenome-Wide Association Studies of Red Cell Distribution Width Identifies Key Associations with Pulmonary Hypertension. Annals of the American Thoracic Society, 2019, 16, 589-598.	3.2	16
45	Postdeployment Respiratory Syndrome in Soldiers With Chronic Exertional Dyspnea. American Journal of Surgical Pathology, 2021, 45, 1587-1596.	3.7	16
46	Renin-Angiotensin-Aldosterone System Modulates Blood Pressure Response During Vascular Endothelial Growth Factor Receptor Inhibition. JACC: CardioOncology, 2019, 1, 14-23.	4.0	15
47	The polygenic architecture of left ventricular mass mirrors the clinical epidemiology. Scientific Reports, 2020, 10, 7561.	3.3	13
48	NHLBI-CMREF Workshop Report on Pulmonary Vascular DiseaseÂClassification. Journal of the American College of Cardiology, 2021, 77, 2040-2052.	2.8	13
49	National Institutes of Health Career Development Awards for CardiovascularÂPhysician–Scientists. Journal of the American College of Cardiology, 2015, 66, 1816-1827.	2.8	12
50	Plasma hepatocyte growth factor is a novel marker of AL cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 242-248.	3.0	12
51	Integration of Complex Data Sources to Provide Biologic Insight into Pulmonary Vascular Disease (2015 Grover Conference Series). Pulmonary Circulation, 2016, 6, 251-260.	1.7	11
52	Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop. Circulation: Heart Failure, 2021, 14, .	3.9	11
53	Reduced freeâ€living activity levels in pulmonary arterial hypertension patients. Pulmonary Circulation, 2019, 9, 1-3.	1.7	10
54	Echocardiographic evaluation of diastolic function in the setting of pulmonary hypertension. Pulmonary Circulation, 2019, 9, 1-11.	1.7	9

#	Article	IF	CITATIONS
55	A checkpoint on innate myeloid cells in pulmonary arterial hypertension. Pulmonary Circulation, 2019, 9, 1-5.	1.7	9
56	BMI Is Causally Associated With Pulmonary Artery Pressure But Not Hemodynamic Evidence of Pulmonary Vascular Remodeling. Chest, 2021, 159, 302-310.	0.8	9
57	Clinical Features Associated With Nascent Left Ventricular Diastolic Dysfunction in a Population Aged 40 to 55 Years. American Journal of Cardiology, 2018, 121, 1552-1557.	1.6	8
58	Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension. Pulmonary Circulation, 2022, 12, e12028.	1.7	8
59	Autonomic Nervous System in Pulmonary Arterial Hypertension. Circulation, 2018, 137, 925-927.	1.6	7
60	Minimally invasive fibrillating mitral valve replacement for patients with advanced cardiomyopathy: A safe and effective approach to treat a complex problem. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 2045-2051.e1.	0.8	6
61	Vasodilator-Responsive Idiopathic Pulmonary Arterial Hypertension: Evidence for a New Disease?. Annals of Internal Medicine, 2015, 162, 148-149.	3.9	6
62	End-Tidal Carbon Dioxide as a Prognostic Feature in Pulmonary Arterial Hypertension. Annals of the American Thoracic Society, 2017, 14, 896-902.	3.2	6
63	Early intervention: should we conduct therapeutic trials for mild pulmonary hypertension before onset of symptoms?. Pulmonary Circulation, 2019, 9, 204589401984561.	1.7	6
64	Association between HIV and incident pulmonary hypertension in US Veterans: a retrospective cohort study. The Lancet Healthy Longevity, 2021, 2, e417-e425.	4.6	6
65	Clinical and genetic associations with prostacyclin response in pulmonary arterial hypertension. Pulmonary Circulation, 2018, 8, 1-9.	1.7	5
66	Measurement of diffuse ventricular fibrosis with myocardial T1 in patients with atrial fibrillation. Journal of Arrhythmia, 2016, 32, 51-56.	1.2	4
67	Pulmonary Hypertension and Right Ventricular Failure. Cardiology Clinics, 2020, 38, 269-281.	2.2	4
68	Severity of Pulmonary Hypertension and Obesity are Not Associated with Worse Functional Outcomes after Pulmonary Thromboendarterectomy. Pulmonary Circulation, 2016, 6, 174-180.	1.7	3
69	Sex hormone exposure and reproductive factors in pulmonary arterial hypertension: a case–control study. Pulmonary Circulation, 2020, 10, 1-9.	1.7	3
70	Using genetics to detangle the relationships between red cell distribution width and cardiovascular diseases: a unique role for body mass index. Open Heart, 2021, 8, e001713.	2.3	3
71	Letter by Mosley Regarding Article, "Iron Homeostasis and Pulmonary Hypertension: Iron Deficiency Leads to Pulmonary Vascular Remodeling in the Rat― Circulation Research, 2015, 117, e56-7. 	4.5	2
72	Correspondence on the debate regarding the haemodynamic definition of pulmonary hypertension. European Respiratory Journal, 2019, 53, 1900727.	6.7	2

#	Article	IF	CITATIONS
73	Pulmonary Artery Acceleration Time in Young Adulthood and Cardiovascular Outcomes Later in Life: The Coronary Artery Risk Development in Young Adults Study. Journal of the American Society of Echocardiography, 2020, 33, 82-89.e1.	2.8	2
74	Biomarker-specific differences between transpulmonary and peripheral arterial–venous blood sampling in patients with pulmonary hypertension. Biomarkers, 2020, 25, 131-136.	1.9	2
75	HIV- and HCV-specific markers and echocardiographic pulmonary artery systolic pressure among United States veterans. Scientific Reports, 2020, 10, 18729.	3.3	2
76	Predictors of Diastolic-To-Wedge Gradient in Patients Evaluated for Pulmonary Hypertension. PLoS ONE, 2013, 8, e76461.	2.5	1
77	One generation's "junk―is another's treasure: The emerging role of microRNAs as therapeutic target Journal of Heart and Lung Transplantation, 2014, 33, 233-234.	<sup>CS.</sup> 0.6	1
78	Toxin-Mediated Myocarditis From a BrownÂRecluse Spider Bite. JACC: Case Reports, 2022, 4, 49-53.	0.6	1
79	Introduction to Review Series on Pulmonary Vascular Disease and Right Ventricular Heart Failure. Circulation Research, 2022, 130, 1362-1364.	4.5	1
80	Moment on the Lips, a Lifetime on the Lungs?. Circulation Research, 2019, 125, 467-469.	4.5	0
81	Editorial commentary: Pulmonary hypertension in left heart disease: Definitions, data sources, and the road ahead. Trends in Cardiovascular Medicine, 2019, 29, 218-219.	4.9	0
82	Floating the invisible swan: noninvasive prediction of haemodynamics. European Respiratory Journal, 2020, 55, 1902385.	6.7	0
83	Echocardiographic Pulmonary Hypertension and Right Heart Function—The Big Picture—Reply. JAMA Cardiology, 2020, 5, 613.	6.1	0
84	Shuttling toward Improved Clinic-based Assessment of Exercise Capacity in Pulmonary Arterial Hypertension. Annals of the American Thoracic Society, 2021, 18, 26-27.	3.2	0
85	Right Ventricular Pathobiology. , 2014, , 35-44.		0
86	SAT-080 Dexamethasone Administration Stimulates Acute Increases in Natriuretic Peptides in Humans: A Potential Diagnostic Test for "Natriuretic Peptide Hormone Deficiency"?. Journal of the Endocrine Society, 2019, 3, .	0.2	0